{
    "root": "4410582a-a5f3-429f-a7ca-5c17fb5560bf",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Pomalyst",
    "value": "20250226",
    "ingredients": [
        {
            "name": "POMALIDOMIDE",
            "code": "D2UX06XLB5",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_72690"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29864"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "SODIUM STEARYL FUMARATE",
            "code": "7CV7WJK4UI",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00815"
        }
    ],
    "indications": {
        "text": "pomalyst thalidomide analogue indicated treatment adult patients : \u2022 combination dexamethasone , patients multiple myeloma ( mm ) received least two prior therapies including lenalidomide proteasome inhibitor demonstrated disease progression within 60 days completion last therapy ( 1.1 ) . \u2022 aids-related kaposi sarcoma ( ks ) failure highly active antiretroviral therapy ( haart ) patients ks hiv-negative . indication approved accelerated approval based overall response rate . continued approval indication may contingent upon verification description benefit confirmatory trial ( ) ( 1.2 ) .",
        "doid_entities": [
            {
                "text": "multiple myeloma (DOID:9538)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_9538"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "kaposi sarcoma (DOID:8632)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8632"
            },
            {
                "text": "sarcoma (DOID:1115)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1115"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 mm : 4 mg per day taken orally days 1 21 repeated 28-day cycles disease progression ( 2.2 ) . refer section 14.1 dexamethasone dosing ( 14.1 ) . \u2022 ks : 5 mg per day taken orally days 1 21 repeated 28-day cycles disease progression unacceptable toxicity ( 2.3 ) . \u2022 modify certain patients renal impairment ( 2.7 , 8.6 ) hepatic impairment ( 2.8 , 8.7 ) .",
        "doid_entities": [
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "dark blue opaque cap yellow opaque body , imprinted `` poml `` cap white ink `` 1 mg `` body black ink 1 mg bottles 21 ( ndc 59572-501-21 ) 1 mg bottles 100 ( ndc 59572-501-00 ) dark blue opaque cap orange opaque body , imprinted `` poml `` cap `` 2 mg `` body white ink 2 mg bottles 21 ( ndc 59572-502-21 ) 2 mg bottles 100 ( ndc 59572-502-00 ) dark blue opaque cap green opaque body , imprinted `` poml `` cap `` 3 mg `` body white ink 3 mg bottles 21 ( ndc 59572-503-21 ) 3 mg bottles 100 ( ndc 59572-503-00 ) dark blue opaque cap blue opaque body , imprinted `` poml `` cap `` 4 mg `` body white ink 4 mg bottles 21 ( ndc 59572-504-21 ) 4 mg bottles 100 ( ndc 59572-504-00 )",
    "adverseReactions": "\u2022 pregnancy ( 4.1 ) \u2022 hypersensitivity ( 4.2 )",
    "indications_original": "POMALYST is a thalidomide analogue indicated for the treatment of adult patients: \u2022 in combination with dexamethasone, for patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy ( 1.1 ). \u2022 with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART) or in patients with KS who are HIV-negative. This indication is approved under accelerated approval based on overall response rate.  Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s) ( 1.2 ).",
    "contraindications_original": "\u2022 MM: 4 mg per day taken orally on Days 1 through 21 of repeated 28-day cycles until disease progression ( 2.2 ). Refer to section 14.1 for dexamethasone dosing ( 14.1 ). \u2022 KS: 5 mg per day taken orally on Days 1 through 21 of repeated 28-day cycles until disease progression or unacceptable toxicity ( 2.3 ). \u2022 Modify the dosage for certain patients with renal impairment ( 2.7 , 8.6 ) or hepatic impairment ( 2.8 , 8.7 ).",
    "warningsAndPrecautions_original": "Dark blue opaque cap and yellow opaque body, imprinted \"POML\" on the cap in white ink and \"1 mg\" on the body in black ink\n                  \n                     \n                     \n                     \n                     \n                        \n                           \n                           \n                              1 mg bottles of 21\n                           \n                           \n                              (NDC 59572-501-21)\n                           \n                        \n                        \n                           \n                           \n                              1 mg bottles of 100\n                           \n                           \n                              (NDC 59572-501-00)\n                           \n                        \n                     \n                  \n                  Dark blue opaque cap and orange opaque body, imprinted \"POML\" on the cap and \"2 mg\" on the body in white ink\n                  \n                     \n                     \n                     \n                     \n                        \n                           \n                           \n                              2 mg bottles of 21\n                           \n                           \n                              (NDC 59572-502-21)\n                           \n                        \n                        \n                           \n                           \n                              2 mg bottles of 100\n                           \n                           \n                              (NDC 59572-502-00)\n                           \n                        \n                     \n                  \n                  Dark blue opaque cap and green opaque body, imprinted \"POML\" on the cap and \"3 mg\" on the body in white ink\n                  \n                     \n                     \n                     \n                     \n                        \n                           \n                           \n                              3 mg bottles of 21\n                           \n                           \n                              (NDC 59572-503-21)\n                           \n                        \n                        \n                           \n                           \n                              3 mg bottles of 100\n                           \n                           \n                              (NDC 59572-503-00)\n                           \n                        \n                     \n                  \n                  Dark blue opaque cap and blue opaque body, imprinted \"POML\" on the cap and \"4 mg\" on the body in white ink\n                  \n                     \n                     \n                     \n                     \n                        \n                           \n                           \n                              4 mg bottles of 21\n                           \n                           \n                              (NDC 59572-504-21)\n                           \n                        \n                        \n                           \n                           \n                              4 mg bottles of 100\n                           \n                           \n                              (NDC 59572-504-00)",
    "adverseReactions_original": "\u2022 Pregnancy ( 4.1 ) \u2022 Hypersensitivity ( 4.2 )",
    "drug": [
        {
            "name": "Pomalyst",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_72690"
        }
    ]
}